PVCT News and Press, Provectus Biopharmaceuticals Inc From 07/29/19

Dr. Akers to assist Provectus develop and manage new Company scientific advisory board KNOXVILLE, TN, July 29, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the addition of Dr. Frank Akers to the Company’s Strategic Advisory Board (“SAB”), effecti...

The USPTO has allowed Provectus' ( OTC:PVCT ) US patent application 15/804,357 for the combination of intratumoral PV-10 and systemic immunomodulatory therapy for the treatment of a range of solid tumor cancers. More news on: Provectus Biopharmaceuticals, Inc., Healthcare stocks new...

- Further patent protection of combinations of intratumoral PV-10 and checkpoint inhibitor (CI) drugs for the treatment of multiple, different, solid tumor cancers KNOXVILLE, TN, July 15, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the United States Patent and Tr...

Metastatic neuroendocrine tumors: Monotherapy data presentations planned. Phase 2 combination therapy trial designs with different classes of checkpoint inhibitor drugs being developed. Metastatic uveal melanoma: Data presentation planned. Patients have received PV-10 monotherapy and als...

No safety concerns identified; no significant overlap of or unexpected toxicities 65% overall ORR with 9% CR (RECIST 1.1) maintained Preliminary PFS of 12.3 months Changes in T cell populations similar to single-agent PV-10 treatment KNOXVILLE, TN, June 03, 2019 (GLOBE NEWSWIRE) ...

No safety concerns identified 50% ORR and 83% disease control of injected lesions Stable Chromogranin A responses and quality of life scores for nearly all subjects KNOXVILLE, TN, June 03, 2019 (GLOBE NEWSWIRE) --  Provectus (OTCQB: PVCT) today announced that preliminary safe...

Metastatic neuroendocrine tumors; Advanced cutaneous melanoma Intratumoral administration of PV-10 to visceral and superficial disease locations Single-agent and combination therapy treatment settings KNOXVILLE, TN, April 17, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today anno...

KNOXVILLE, TN, March 25, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the appointment of Heather Raines as the Company’s Chief Financial Officer (CFO). Mrs. Raines had previously served as Provectus’ Controller since 2017, and now replaces the Companyȁ...

KNOXVILLE, TN, March 21, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updates on the Company's metastatic uveal melanoma drug development program for its lead investigational cancer agent PV-10. Intratumoral injection of small molecule oncolytic immunotherapy PV-10 can yi...

Provides preclinical proof-of-concept data on efficacy of single-agent PV-10 for treatment of neuroblastoma Supports use of checkpoint inhibitors with PV-10 treatment backbone to further enhance activity in patients with relapsed and refractory neuroblastoma KNOXVILLE, TN & NEW YOR...